New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
February 12, 2013
07:17 EDTCYCCCyclacel receives U.S., EU patents for sapacitabine used with HDAC inhibitors
Cyclacel Pharmaceuticals announced the issuance of U.S. Patent No. U.S. 8,349,792 and European Patent No 2,101,790. Both patents include claims to combination treatment of sapacitabine, the Company's lead product candidate, with histone deacetylase, or HDAC, inhibitors. The patents provide exclusivity until June 2029 and December 2027 respectively.
News For CYCC From The Last 14 Days
Check below for free stories on CYCC the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
September 18, 2014
07:06 EDTCYCCCyclacel Pharmaceuticals CYC065 data shows selectivity, activity
Cyclacel Pharmaceuticals announced the presentation of preclinical data demonstrating the therapeutic potential of CYC065, Cyclacel's second-generation cyclin dependent kinase, or CDK, inhibitor, to treat acute leukemias, and in particular those with rearrangements in the mixed lineage leukemia, or MLL, gene. The data showed that in vitro all human acute myelogenous leukemia, or AML, and acute lymphocytic leukemia, or ALL, cell lines with MLL rearrangements, or MLLr, tested were sensitive to CYC065 and that the drug inhibited MLL-driven gene expression. Potent anticancer activity of CYC065 was demonstrated in vivo in AML xenograft models resulting in over 90% inhibition of tumor growth. The data were presented at the 2014 Society of Hematologic Oncology meeting taking place September 17-20, 2014 in Houston, Texas.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the disclaimer & terms of use